Search

for
Search:

Learn

0 / 0 results

— no results

Research

5 / 34 results

research Dietary Intake in Subjects with Early Psychosis: Is There a Relationship with Clinical Subtype or Antipsychotic Treatment?

October 2012 in “European Neuropsychopharmacology”

People with early psychosis eat more calories, saturated fat, and sugar, and the drug olanzapine may lead to eating even more calories.

A Summary of In Vitro, Phase I, and Phase II Studies Evaluating the Mechanism of Action, Safety, and Efficacy of Clascoterone (Cortexolone 17a Propionate, CB-03-01) in Androgenetic Alopecia

research A Summary of In Vitro, Phase I, and Phase II Studies Evaluating the Mechanism of Action, Safety, and Efficacy of Clascoterone (Cortexolone 17a Propionate, CB-03-01) in Androgenetic Alopecia

3 citations, August 2019 in “Journal of The American Academy of Dermatology”

Clascoterone safely promotes hair growth similar to minoxidil.

research Topical Solutions for Androgenetic Alopecia: Evaluating Efficacy and Safety

July 2024 in “Forum Dermatologicum”

Topical treatments for hair loss can be effective but need careful safety evaluation.

research New Developments in the Molecular Treatment of Ichthyosis: Review of the Literature

21 citations, July 2022 in “Orphanet journal of rare diseases”

New treatments for ichthyosis, like protein replacement and gene therapy, show promise and may become standard care.

research Symmetry of Upper Eyelid After Unilateral Blepharoptosis Repair with Minimally Invasive Conjoint Fascial Sheath Suspension Technique

December 2023 in “International journal of ophthalmology”

The technique effectively improved upper eyelid symmetry in patients with mild and moderate blepharoptosis.

View more "poc study" in research →

Community Join

5 / 5 results

community Replicel, worthy of hype or probable disappointment? Questions thread

6 upvotes 8 years ago

The conversation discusses the potential of Replicel/Shiseido treatment for hair loss, questioning its effectiveness, whether it grows new follicles, and its market release timeline. It also compares Replicel to other competitors like Kyocera/RIKEN/Tsuji.

community Disappointing news on Breezula/CB-03-01

22 upvotes 5 years ago

The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.

community Only 10 more days until cassiopea releases their 12 month results for CB-03-01 our best hope of an alternative to finasteride

in Finasteride 151 upvotes 5 years ago

The conversation discusses anticipation for CB-03-01, a potential new hair loss treatment that may be more effective and have a cleaner safety profile than finasteride. Users are hopeful but cautious, discussing current treatments like minoxidil, nizoral, and dermarolling, and the possibility of combining them with CB-03-01 for better results.

community Cassiopea announces completion of recruitment of Phase II dose ranging trial of Breezula (CB-03-01) for androgenic alopecia

11 upvotes 6 years ago

The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

community Hope Medicine HMI-115 got 28M$ investment

in Research/Science 58 upvotes 9 months ago

Hope Medicine received a $28M investment for HMI-115, a monoclonal antibody in phase II trials for treating androgenetic alopecia. Some users are skeptical about its effectiveness, while others find the investment and trial results encouraging.